Background: Anxious temperament (AT) is identifiable early in life and predicts the later development of anxiety disorders and depression. Neuropeptide Y (NPY) is a putative endogenous anxiolytic neurotransmitter that adaptively regulates responses to stress and might confer resilience to stress-related psychopathology. With a well-validated nonhuman primate model of AT, we examined expression of the NPY system in the central nucleus (Ce) of the amygdala, a critical neural substrate for extreme anxiety.
A nxious temperament (AT) is a dispositional trait that, when present early in life, increases the risk for the subsequent development of anxiety and depressive disorders (1) (2) (3) . We have established a nonhuman primate model of childhood AT, facilitating the identification of the neural mechanisms underlying the development of early life anxiety. In rhesus monkeys, AT is assessed as a composite of threat-induced freezing behavior, inhibition of vocalizations, and increased plasma cortisol levels (4, 5) . We previously demonstrated that metabolic activity in the central nucleus (Ce) of the amygdala, indexed with high-resolution [ 18 F]-fluorodeoxyglucose positron emission tomography (FDG-PET), strongly predicts individual differences in AT (6, 7) . Moreover, we demonstrated a mechanistic role for the Ce as selective lesions decrease AT (8) . To understand the molecular mechanisms in the Ce that underlie the at-risk AT phenotype, we recently performed a transcriptome-wide search for AT-related messenger RNA (mRNA) expression within the Ce (9) . Among our significant results, we found that increased levels of neuropeptide Y receptor 1 (NPY1R) mRNA predict decreased levels of AT. This finding is of particular interest because of the hypothesized role of neuropeptide Y (NPY) in anxiety-like responding and as a resilience factor for stressrelated psychopathology. The current study expands on our NPY1R mRNA finding by identifying a similar relationship between NPY5R mRNA levels in the Ce and AT. We also provide the first detailed description of NPY1R and NPY5R mRNA distribution in the primate amygdala and associated regions. Lastly, we demonstrate a relationship between NPY1R and NPY5R mRNA levels in the Ce and metabolic activity in cortical brain regions that have the ability to regulate the Ce.
There is growing evidence that NPY, a 36-amino acid peptide, is a stress-modulating resilience factor (10) (11) (12) . Moreover, alterations in NPY signaling have been linked to anxiety, depressive, eating, and substance-abuse disorders (10, 13, 14) . Neuropeptide Y is widely expressed in the brain, with high levels present in several brain regions that play a role in modulating the response to potential threat, including the amygdala and hippocampus (10) . Work in rodents demonstrates that NPY participates in the regulation of anxiety-like responses (15) (16) (17) (18) (19) (20) (21) and has marked anti-stress effects (10, 22) .
The NPY family includes NPY, which is expressed in the central and peripheral nervous systems as well as pancreatic polypeptide and peptide YY (PYY), which are expressed in the gut (23) . The actions of these peptides are mediated by several G proteincoupled, seven-transmembrane domain receptors, including: Y 1 , Y 2 , Y 4 , Y 5 , and y 6 (24) . Although the NPY6R gene is functional in rabbits and mice, it is absent in rats and considered a pseudogene in primates and pigs (25) (26) (27) . Receptor signaling is mediated by pertussis toxin-sensitive G i/o proteins and, depending on the celltype in which they are expressed, can inhibit cyclic adenosine monophosphate formation, alter intracellular calcium ion mobilization, and modulate calcium ion and potassium ion channels (28) . There is considerable evidence linking Y 1 , Y 2 , and Y 5 to the effects that central NPY exerts on anxiety-like responding (29) (30) (31) (32) . The anxiolytic responses to NPY administration are thought to be mediated in part by Y 1 and, to a lesser extent, Y 5 in the amygdala (20, 33) , hippocampus (15) , septum (34) , and locus coeruleus (35) . In contrast, activation of Y 2 is thought to produce anxiogenic-like responses (30, (36) (37) (38) .
To assess the contribution of the NPY system to early-life AT in primates, we focused on mRNA expression levels in the Ce, a key component of the AT neural circuit. Our aim was to extend our earlier microarray findings by examining relations between expression levels of all members of the NPY system in the Ce, AT, and brain metabolism, indexed with FDG-PET. To understand the selectivity of the effects of the Ce NPY system in relation to AT, we also assessed the relationship between NPY system gene expression in a region that is not a core component of the neural circuit underlying AT, the motor cortex (6,7). Moreover, because there is no detailed description of NPY1R and NPY5R mRNA levels in either the human or nonhuman primate amygdala, we also used in situ hybridization to characterize expression patterns for NPY1R and NPY5R mRNA across the major amygdala nuclei and adjacent brain regions. Lastly, to define potential neural circuits that underlie the influences of the NPY system on AT, we looked at metabolic activity throughout the brain to identify regions outside of the Ce where variation in metabolism is correlated with NPY1R or NPY5R mRNA levels in the Ce.
Methods and Materials

Overview
Methods were similar to those previously described in detail and are only briefly summarized here (7, 12) . A detailed description of the subjects as well as select methods that were not employed in prior work by our group is provided in Supplement 1. We assessed individual differences in the AT phenotype and brain metabolic activity with the well-validated, widely used No-Eye Contact condition of the human intruder paradigm and highresolution FDG-PET. The AT phenotype was defined as a composite score of behavioral (increased freezing and decreased coo vocalizations) and hormonal measures (increased plasma cortisol) in response to the mildly threatening No-Eye Contact challenge. A magnetic resonance imaging scan was acquired in a separate session to aid in image registration. At the end of the study, subjects were sacrificed, and brain tissue was obtained from the Ce and motor cortex for RNA extraction and quantification by microarray analysis and quantitative real-time polymerase chain reaction (qRT-PCR). A series of regression models was used to test relations between AT and mRNA expression levels for members of the NPY family that were detectable in the Ce (NPY, NPY1R, NPY2R, and NPY5R); it was not possible to reliably quantify pancreatic polypeptide, PYY, or NPY4R. In cases where expression levels predicted AT (NPY1R and NPY5R), we used in situ hybridization to assess the pattern of expression across the amygdala and neighboring regions. We also used whole-brain FDG-PET to test whether mRNA expression levels in the Ce (ex vivo) are correlated with metabolism in distal regions of the brain (in vivo).
Results
Elevated NPY1R and NPY5R mRNA Levels in the Ce Selectively Predict Decreased AT We previously demonstrated that metabolic activity in the rhesus Ce strongly predicts individual differences in AT (7) ( Figure 1A ,B,C) and that the NPY1R was one of 139 genes that had mRNA expression levels in the Ce as determined by microarray analysis that predicted significant variation in the AT phenotype (false discovery rate q Ͻ .05) (9) . Given the known role of the NPY system in anxiety-like responding, in the present study we sought to define the relationship between AT, Ce metabolism, and the expression of all members of the NPY family of genes. As shown in Figures 1D and 1E , analyses of qRT-PCRdetermined gene expression levels in the Ce revealed significant negative correlations between AT and both NPY1R (t ¼ À2.28; p ¼ .035) and NPY5R (t ¼ À2.55; p ¼ .020). Interestingly, there was a trend for NPY1R and NPY5R mRNA levels to be correlated with each other in the Ce (r ¼ .35, p ¼ .11). In contrast, AT was unrelated to variation in the expression of NPY (t ¼ .6, p ¼ .553) and NPY2R (t ¼ À1.56, p ¼ .135) in the Ce. It was not possible to reliably quantify PYY or NPY4R, likely due to very low levels of expression in the Ce. The NPY6R mRNA was not included in our analysis, because it is considered a nonfunctional pseudogene in primates (27) . Collectively, these results replicate our published gene chip finding on the NPY1R and extend these results to the NPY5R by demonstrating an anatomically selective relationship between mRNA expression levels in the Ce and AT expression.
To assess the regional selectivity of the correlation between NPY1R mRNA and AT as well as NPY5R mRNA and AT, we examined mRNA expression levels for these two genes in a region of the motor cortex that is not a core component of the neural substrate underlying AT (7) . Gene expression analysis with qRT-PCR did not reveal a significant correlation between AT and motor cortex expression levels for either
Additionally, there was no significant association between NPY1R mRNA levels in the motor cortex and Ce (r ¼ .37, p ¼ .084) or NPY5R mRNA levels in the motor cortex and Ce (r ¼ .18, p ¼ .41). The motor cortex is a brain region involved in the expression of locomotion (9), and highlighting the anxiety-specific nature of these results, there was no significant correlation between motor cortex NPY1R or NPY5R mRNA levels and locomotion (NPY1R: t ¼ .05, p ¼ .957; and NPY5R: t ¼ .23, p ¼ .824).
Expression Pattern for NPY1R and NPY5R mRNA in the Nonhuman Primate Amygdala and Neighboring Regions
To assess the regional expression of NPY1R and NPY5R mRNA in the rhesus amygdala, in situ hybridization was performed with tissues slices obtained through the same region of the Ce that was used for PCR analysis in the other hemisphere. The pattern of NPY1R and NPY5R hybridization signals are shown in Figure 2 . For NPY1R mRNA, hybridization signals are seen throughout the entire extent of the amygdala. Qualitatively, the highest levels of expression are found in the lateral and medial nuclei, amygdalopiriform cortex transition area and the ventral cortical amygdala nucleus. Moderate levels of expression are seen in the Ce and parvicellular division of the basomedial nucleus. For the NPY5R mRNA, a diffuse signal throughout the extent of the amygdala was observed. This signal was considerably weaker than the NPY1R signal, necessitating a significantly longer exposure time on the phosphor screen (13 days vs. 1 day for NPY1R mRNA). However, it is evident that there are relatively high levels of expression in the medial amygdala, moderate levels of expression in the lateral amygdala, and relatively low levels of expression in the Ce (Figure 2) . Interestingly, because half the samples were obtained from each hemisphere, it was possible to use our qRT-PCR data to assess hemispheric differences in expression within the Ce. The levels of NPY1R mRNA did not differ between hemispheres (left .80 Ϯ .08; n ¼ 11 vs. right .67 Ϯ .04; n ¼ 12; t ¼ 1.47; p ¼ .16), but NPY5R mRNA levels were 20% higher in the left hemisphere compared with the right hemisphere (left 2.18 Ϯ .14; n ¼ 11 vs. right 1.81 Ϯ .08; n ¼ 12; t ¼ 2.34; p ¼ .029).
These tissue sections provided us with the opportunity to examine mRNA expression patterns in other brain regions that are present in the same anterior/posterior plane as the amygdala. For NPY1R mRNA, the strongest signals are present throughout the cortex. These cortical signals tended to be laminar-specific, and in general the signals were strongest in the superficial and deep cortical layers and less intense in the middle layers, although this pattern was less evident in the temporal cortex. In addition, the cortical signals were most intense in the ventral half of the tissue section and include the somatosensory cortex, superior temporal sulcus, insular cortex, temporal cortex, and entorhinal cortex. There is also significant expression in the anterior cingulate and ventral medial region of the head of the caudate nucleus. Although the full extent of the claustrum contained in this section has moderate levels of NPY1R expression, the strongest expression is seen at the ventral tip and represents some of the strongest expression in the entire section. There was also significant expression seen in several midline structures, including the stria terminalis, retrochiasmatic part of the supraoptic nucleus, arcuate nucleus, anterior paraventricular region of the thalamus, and the septo-hippocampal nucleus. For NPY5R mRNA, there is a diffuse signal throughout the extent of the section including regions of the temporal cortex and somatosensory cortex that was less laminar-specific in comparison with NPY1R mRNA. There are also signals in the ventral tip of the claustrum, internal capsule, and a band across the central portion of the putamen. The most intense mRNA signals are in midline structures including the optic tract, retrochiasm of the supraoptic nucleus, and the medial division of the arcuate nucleus.
Assessing the Relationship Between NPY1R and NPY5R Gene Expression and Metabolism Throughout the Brain
We used whole-brain voxel-wise regressions to identify brain regions where NPY1R or NPY5R mRNA levels significantly predict metabolism (p Ͻ .005, uncorrected) (for detailed results, see Tables 1 and 2 ). As shown in Figure 3 , individuals with higher levels of NPY1R mRNA in the Ce were characterized by increased metabolism in the right dorsolateral prefrontal cortex (dlPFC) and decreased metabolism in the pregenual anterior cingulate cortex (pgACC). As shown in Figure 4 , individuals with higher levels of NPY5R mRNA in the Ce were characterized by increased metabolism in the dorsal prefrontal cortex (dPFC; area 8). In terms of Ce metabolic activity, the mean FDG-PET signal extracted from the 95% confidence interval most predictive of AT ( Figure 1 ) showed a weak trend toward a significant negative correlation with NPY5R mRNA levels as assessed by qRT-PCR analysis (t ¼ À1.63, p ¼ .12). There was no significant correlation with NPY1R mRNA (t ¼ À.01, p ¼ .99).
Discussion
The current work links the NPY system to AT by examining the expression of NPY system genes in the Ce. Specifically, we Regions with a significant correlation (p Ͻ .05, two-tailed uncorrected) between metabolic activity and NPY1R messenger RNA expression as assessed by quantitative real-time polymerase chain reaction. . ACC, anterior cingulate cortex; APir, amygdalopiriform cortex; Arc, arcuate nucleus; BL, basolateral amygdala; BM, basomedial amygdala; Cd, caudate nucleus; Cl, claustrum; Ent, entorhinal cortex; ic, internal capsule; Ins, insular cortex; La, lateral amygdala; Me, medial amygdala; opt, optic tract; PMCx, primary motor cortex; PrMCx, premotor cortex; Pu, putamen; PVA, anterior paraventricular region of the thalamus; SHi, septo-hippocampal nucleus; SOR, retrochiasm of the supraoptic nucleus; st, stria terminalis; STS, somatosensory cortex; sts, superior temporal sulcus; Temp, temporal cortex; VCo, ventral cortical amygdala nucleus.
demonstrate that individuals with increased expression of NPY1R or NPY5R mRNA in the Ce are characterized by lower levels of the anxious phenotype. We expanded on these findings to describe the distribution of NPY1R and NPY5R mRNA in the rhesus amygdala and surrounding regions. Lastly, we identify several brain regions where metabolic activity is predicted by the Ce expression of the NPY1R or NPY5R genes.
The inverse relationship between AT and NPY1R and NPY5R mRNA levels suggests that lower anxiety levels are accompanied by increased NPY receptor expression in the Ce, which is consistent with studies indicating that Y 1 and Y 5 mediate the anxiolytic-like effects of NPY in the brain (29, 31, 32) . Because extreme and stable AT is a risk factor for the development of psychopathology, the current results are in agreement with the postulated role of the NPY neurotransmitter system as a resilience factor that decreases the risk to develop stress-related psychopathology (39) . It should be noted that the studies reported here assessed NPY receptor mRNA levels; confirmation of the mRNA findings at the protein level would provide further confidence in the results. Although there is often strong agreement between variations in mRNA and protein levels, ultimately our findings need to be confirmed at the protein level with immunodetection or in vitro autoradiography.
We failed to find a significant relationship-consistent with a Ce-specific regulation of NPY-receptor gene expression in ATbetween AT and NPY1R and NPY5R mRNA expression in motor cortex, which is not a core component of the AT circuit. The levels of NPY1R and NPY5R mRNA in the motor cortex were not correlated with locomotion even though motor cortex metabolic activity was correlated with locomotion, consistent with an AT-specific relationship. Moreover, NPY1R and NPY5R mRNA levels in the motor cortex were not significantly correlated with expression in the Ce. These results indicate that the relationship between NPY1R and NPY5R mRNA levels and AT is not general across brain regions and that the correlations are not simply nonspecific markers for brain metabolism or other behaviors.
It is interesting that mRNA levels for both NPY1R and NPY5R show an inverse correlation with AT. In humans, the genes for these two receptors are located on the same region of chromosome 4 in opposite orientations and share common transcriptional control regions (40) . A search of the rhesus genome reveals a similar organization with these two genes located on chromosome 5 in opposite orientations. It is possible that in the Ce there are shared transcription factors that control the amount of expression of these two genes, which is consistent with the observed trend for a correlation between NPY1R and NPY5R mRNA levels in the Ce. Understanding the regulation of the transcription factors that control expression of these two genes in the Ce sets the stage for identifying novel targets for pharmacological manipulation of NPY receptor expression in relation to anxiety.
It is possible that the variations in NPY receptor mRNA levels are determined by DNA sequence variation in the promoter Regions with a significant correlation (p Ͻ .05, two-tailed uncorrected) between metabolic activity and NPY5R messenger RNA expression as assessed by quantitative real-time polymerase chain reaction. Figure 3 . The Ce NPY1R mRNA levels predicted metabolism in the prefrontal and cingulate cortices. Voxel-wise analysis revealed that Ce NPY1R mRNA levels predicted (A) increased metabolism in the right (R) dorsolateral prefrontal cortex and (B) decreased metabolism in the pregenual anterior cingulate. Color variation represents level of statistical significance as defined in horizontal color bars with shades of red through yellow for positive correlations and shades of blue for negative correlations. Other abbreviations as in Figure 1. region of the NPY1R and NPY5R genes. In fact, there is evidence that a polymorphism in the promoter region of the human NPY gene (single nucleotide polymorphism rs16147) regulates the level of NPY mRNA and protein in the brain and is associated with differences in stress responsiveness and anxiety symptoms (41, 42) . Moreover, polymorphisms in the NPY1R and NPY5R genes have been linked to drug addiction and variations in diet (43) (44) (45) . In future studies it will be of value to determine whether these variations exist in the rhesus monkey and whether they influence the function of the brain NPY system in relation to anxiety.
The rhesus monkey model of extreme AT is associated with persistently elevated levels of anxiety as well as chronically elevated Ce metabolism (7) . Although NPY receptor expression is not related to Ce metabolism in this study, it is possible that the decreased levels of NPY receptor expression impair NPY signaling, resulting in extreme AT. Conversely, there might be an increase in NPY signaling in an attempt to compensate for the extreme AT phenotype that then results in downregulation of Ce NPY1R and NPY5R expression. Few previous reports have described the role of the Y 5 in anxiety-like responding, in part, because of the lack of selective ligands that differentiate between the various NPY receptor subtypes. Furthermore, outside of hypothalamic regions, Y 5 is expressed at significantly lower levels compared with the Y 1 receptor. The present study highlights the important role of the Y 5 in AT and anxiety in general, suggesting that future studies aimed at more fully delineating the role of the Y 5 in the anxietylike responding are likely to prove fruitful.
This study is the first to provide a detailed description of the expression of NPY1R and NPY5R mRNA in the amygdala and neighboring regions in nonhuman primates. The signal for NPY1R mRNA was strong and widespread in several cortical areas, consistent with prior reports in humans (46) (47) (48) . Although there are no published studies describing the mRNA distribution of NPY1R in the rhesus brain, a PET and in vitro autoradiography study employing 18 F-Y1-973 revealed patterns of receptor localization that are in general agreement with our observations (49) . The widespread distribution throughout the cortex is also seen in the rat and mouse brain where Npy1r mRNA is detectable in essentially all cortical fields (50) . In all of these species, there is a layer specific pattern to the NPY1R mRNA expression with the layers of highest expression varying between cortical regions and between species. Regarding the expression pattern of NPY1R mRNA in the amygdala, only limited information is available for the primate brain, with moderate expression levels being reported in the human amygdala, but the report did not assess the differential distribution across the various amygdala nuclei (47, 48) . In the rat amygdala, the highest mRNA expression is seen in the amygdalohippocampal transition area, amgydala-piriform transition area, anterior basomedial nucleus and posteroventral medial nucleus, while a small number of intensely labelled cells are present in the Ce, and weakly labeled cells were scattered throughout the basomedial, basolateral, and lateral nuclei. Similar mRNA expression patterns are seen in the mouse (50) (51) (52) . The mRNA expression patterns are in general agreement with two detailed studies examining Y 1 immunoreactivity in rat brain (51, 53) . The expression pattern in the rodent amygdala is very similar to that described in the present study for the rhesus amygdala and suggests there is significant cross-species conservation in the expression of the NPY1R transcript. The expression of the NPY5R mRNA as determined by in situ hybridization tended to be less robust and more localized to hypothalamic and amygdala regions compared with the NPY1R mRNA expression. There have been several published reports describing the mRNA distribution of NPY5R in the rodent brain (54) (55) (56) (57) (58) . The results from these studies are in general agreement with the mRNA expression pattern reported here and previously reported in the human brain (58, 59 ). There were regions of common expression between the NPY1R and NPY5R, and these included the Ce and lateral and medial nuclei of the amygdala as well as supraoptic nucleus, arcuate nucleus, and temporal and somatosensory cortex. This is consistent with studies in the rat brain, where the presence of Npy5r mRNA always corresponded with the presence of Npy1r mRNA but not vice versa (54) . This might arise from the overlapping structure of these genes on the chromosome and the shared transcriptional control elements. The significantly higher Ce expression of NPY5R mRNA in the left hemisphere compared with the right is noteworthy in light of evidence describing hemispheric difference in the control and expression of emotion via the amygdala (60) .
In terms of NPY1R and NPY5R mRNAs in relation to metabolic activity of the Ce region, there was no significant correlation with glucose metabolism in the Ce. Nevertheless, whole-brain voxelwise analyses revealed several other regions where NPY1R or NPY5R mRNA expression predicted metabolism. Brain regions that had metabolic activity that were significantly correlated with NPY1R expression included the dlPFC and pgACC. Similarly, for the NPY5R mRNA, regions with metabolic activity that significantly positively correlated with mRNA levels in the Ce included the dPFC. These prefrontal cortical regions have previously been shown to be part of the circuit that regulates the activity of the amygdala (61, 62) . Thus, our data suggest that NPY1R and NPY5R mRNA levels in the Ce might be regulated by the influences of prefrontal cortex on the NPY1R-and NPY5R-expressing neurons. Alternatively, NPY1R-or NPY5R-expressing Ce neurons could modulate metabolism in these brain regions via direct or indirect mechanisms.
It is very relevant that variations in Ce NPY receptor mRNA expression that are associated with AT are also associated with variations in the metabolic activity of the pgACC and right dlPFC. This is because alterations in both of these brain regions have been associated with anxiety disorders. For example, generalized anxiety disorder has been linked to impaired functional connectivity between the pgACC and the amygdala (63) . In addition, adolescents with generalized anxiety disorder show greater activation to fearful faces in a distributed network centered on the anterior cingulate cortex (64) . With regard to the right dlPFC, high-frequency (10-Hz) repetitive transcranial magnetic stimulation of this region has been shown to decrease anxiety symptoms in posttraumatic stress disorder (65) .
In conclusion, NPY1R and NPY5R mRNA expression levels within the Ce are negatively correlated with AT and predict altered metabolic activity in prefrontal regions that are thought to regulate the amygdala. Higher levels of expression of these receptor subtypes would be expected to increase the capacity for NPY signaling in this region. The NPY in the amygdala has been hypothesized to suppress anxiety-like responding, and NPY has a putative role as a resilience factor. It is possible that children that express more NPY receptors in the Ce region might have a lowered anxiety response to threatening situations that might protect against the development of stress-related psychopathologies such as anxiety and depression. Moreover, these data suggest a potential link between prefrontal metabolic mechanisms and Ce molecular mechanisms that might underlie resilience. Future studies aimed at genetic manipulation of the NPY system in the Ce in rodent as well as primate species will provide additional evidence to support this hypothesis. Because the present findings are directly relevant to at-risk early anxious dispositions, treatment strategies targeting the NPY system might have therapeutic benefit in the prevention of stress-related anxiety disorders in at-risk children. It will also be of interest to determine whether behavioral treatments that promote resilience impact the NPY system.
